IL37 and inflammatory bowel disease: However, despite the shared genetic risk factors in the IL-23/IL-17 pathway, and a positive response to IL-23 inhibitors in psoriasis/PsA and IBD, the efficacy of IL-17i in SpA-related conditions varies.